EastGate Pharmaceutical Token (EGP)

EastGate Pharmaceutical Token (EGP)

Created using Figma
EastGate Pharmaceutical Token (EGP). Creating solutions to vital pharmaceutical problems by merging pharmacy with blockchain. EGP Token would be used to make payments in pharmaceutical stores across the world.
Gegevens zijn niet beschikbaar
1 jun. 2023
31 jul. 2023
100% voltooid
Opgehaald geld - geen gegevens
pet 150 000.00
Harde dop 10 000 000.00
past
Details token
Ticker
EGP
Totale voorraad
100,000,000,000
Token Distributie
Token Sale Program - 60%
Reserve Fund - 8%
Team and Founders - 15%
Board Advisors - 4%
Ecosystem Development - 7%
Marketing and Bounty - 6%
Funds allocation:
Engineering and Development - 40%
Business Development - 12%
Marketing & Promotion - 20%
Legal & Regulation - 10%
Operational & Administration - 8%
Contingency - 4%
Partners - 6%
Geaccepteerde valuta's
ETH, BTC, BCH, BNB, USDT, DOGE, XRP, TRX
Min. Bijdrage
0.01
USDT
aanvullende details
Categorieën
cryptogeld, Gezondheid, betalingen

Over EastGate Pharmaceutical Token (EGP)

EastGate Biotech Corp. is a dynamic biotech company concentrating on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. We are developing a technology platform for enhanced drug delivery designed to provide alternative administration of known drugs with the goal of offering patient-friendly products to improve compliance and increase health benefits to fit today's health-conscious lifestyles. At the present time our technology focuses on the delivery of insulin via a liquid insulin mouth solution based on proprietary composition, but we believe that our technology may also be applicable to the delivery of other active pharmaceutical ingredients. We may also develop other novel formulations of pharmaceutical and natural products. The company has identified several biologically active existing molecules that address unmet needs of patients, especially those with ever-growing chronic conditions.

The company will focus on validating its delivery technology platform and determining different applications for expanding therapeutic treatments. The company intends to out-license different applications. We have not entered into any definitive agreements with respect to the foregoing and there is no guarantee that the Company will enter into such agreements on favorable terms or at all.

Our secondary goal is to leverage our technology for the oral delivery of other active pharmaceutical ingredients for the treatment of non-diabetes indications. If we are successful in obtaining regulatory approval, we may also out-license our intellectual property to other pharmaceutical companies.

% naam% Roadmap

  • March 2022

  • Start of the ERC20 Crypto Platform Development
  • April 2022

  • Start of the Preparation for the ERC20 Token Testing
  • August 2022

  • Deployed Our ERC20 Token (EGP) Over Main Network
  • February 2023

  • Presale Starts
  • Lees verder
  • April 2023

  • Presale Ends
  • May 2023

  • Listing on 2 CEX platforms
  • November 2023

  • Collaboration with top pharmaceutical stores across the world to accept EGP token as payment in stores for pharmaceutical services and items
  • July 2024

  • Training of 10,000 pharmacists to make positive impact in the health field
  • September 2024

  • Launch of EastGate blockchain

EastGate Pharmaceutical Token (EGP) Team

geverifieerd 0%

Aandacht. Het risico bestaat dat niet-geverifieerde leden feitelijk geen lid zijn van het team

Rose Perri
Chief Executive Officer
geverifieerde
Bill Abajian
Chairman, President and Chief Operating Officer
geverifieerde
Anna Gluskin
Chairman Emeritus
geverifieerde

EastGate Pharmaceutical Token (EGP) Laatste nieuws

  • Omdat er mogelijk tijdsverschillen zijn in informatie-updates, moet nauwkeurige informatie over elk ICO-project worden geverifieerd via de officiële website of andere communicatiekanalen.
  • Deze informatie is geen suggestie of advies over beleggen in ICO-financiering. Onderzoek de relevante informatie zelf grondig en besluit over ICO-deelname.
  • Als u denkt dat er problemen of problemen zijn die moeten worden gecorrigeerd voor deze inhoud, of als u uw eigen ICO-project wilt indienen dat wordt vermeld, e-mail ons.
Lees de disclaimer en risicowaarschuwing. Laat disclaimer en risicowaarschuwing zien.